NCT05790213

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

Phase II Trial of Focal Prostate Ablation Combined With Androgen Deprivation Therapy for Prostate Cancer Treatment

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 57 (estimated)
• Sponsor: University of Chicago · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Androgen Deprivation Therapy (ADT)	ADT will be given for 3 months. Participants will receive a standard ADT as chosen by their study doctor.
PROCEDURE	Focal prostate ablation (focal therapy)	Focal prostate ablation (focal therapy) is a surgical procedure to destroy cancer cells by destroying a portion of the prostate instead of the whole prostate.

Timeline

• Start date: 2025-05-05
• Primary completion: 2028-12-18
• Completion: 2028-12-18
• First posted: 2023-03-30
• Last updated: 2025-06-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study